Ângela Sena-Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ângela Sena-Lopes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Fabiana Kömmling Seixas
Molecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Postgraduate Program in Biotechnology, Technological Development Center, Federal University of Pelotas, Pelotas, Brazil
2 shared publications - Lucielli Savegnago
Technologic Development Center, Biotechnology Unit, Neurobiotechnology Research Group, Federal University of Pelotas, Pelotas, RS, Brazil
2 shared publications - Raquel Nascimento das Neves
Laboratório de Farmacologia e Bioquímica do Câncer (LabCancer), Departamento de Farmacologia, Centro de Ciências Biológicas (CCB), Universidade Federal de Santa Catarina (UFSC), Florianópolis, Santa Catarina, 88040-900, Brazil; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA
2 shared publications - Tiago Collares
University Hospital, Federal University of Pelotas - HUBrasil
2 shared publications - Angela Maria Casaril
Technologic Development Center, Biotechnology Unit, Neurobiotechnology Research Group, Federal University of Pelotas, Pelotas, RS, Brazil
1 shared publication - Diego Alves
Federal University of Pelotas
1 shared publication
Latest Publications
- Open Access
- 11 February 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-13
Antiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses
Background: Trichomonas vaginalisis the causative agent of trichomoniasis, which is one of the most common sexually transmitted diseases worldwide. Trichomoniasis has a high incidence and prevalence and is associated with serious complications such as HIV transmission and acquisition, pelvic inflammatory disease and preterm birth. Although trichomoniasis is treated with oral metronidazole (MTZ), the number of strains resistant to this drug is increasing (2.5–9.6%), leading to treatment failure. Therefore, there is an urgent need to find alternative drugs to combat this disease.Methods: Herein, we report thein vitroandin silicoanalysis of 12 furanylN-acylhydrazone derivatives (PFUR 4, a-k) againstTrichomonas vaginalis.Trichomonas vaginalisATCC 30236 isolate was treated with seven concentrations of these compounds to determine the minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC50). In addition, compounds that displayed anti-T. vaginalisactivity were analyzed using thiobarbituric acid reactive substances (TBARS) assay and molecular docking. Cytotoxicity analysis was also performed in CHO-K1 cells.Results: The compounds PFUR 4a and 4b, at 6.25 µM, induced complete parasite death after 24 h of exposure with IC50of 1.69 µM and 1.98 µM, respectively. The results showed that lipid peroxidation is not involved in parasite death. Molecular docking studies predicted strong interactions of PFUR 4a and 4b withT. vaginalisenzymes, purine nucleoside phosphorylase, and lactate dehydrogenase, while only PFUR 4b interactedin silicowith thioredoxin reductase and methionine gamma-lyase. PFUR 4a and 4b led to a growth inhibition (< 20%) in CHO-K1 cells that was comparable to the drug of choice, with a promising selectivity index (> 7.4).Conclusions: Our results showed that PFUR 4a and 4b are promising molecules that can be used for the development of new trichomonacidal agents forT. vaginalis.
- 11 February 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-13
Open AccessAntiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses
Background: Trichomonas vaginalisis the causative agent of trichomoniasis, which is one of the most common sexually transmitted diseases worldwide. Trichomoniasis has a high incidence and prevalence and is associated with serious complications such as HIV transmission and acquisition, pelvic inflammatory disease and preterm birth. Although trichomoniasis is treated with oral metronidazole (MTZ), the number of strains resistant to this drug is increasing (2.5–9.6%), leading to treatment failure. Therefore, there is an urgent need to find alternative drugs to combat this disease.Methods: Herein, we report thein vitroandin silicoanalysis of 12 furanylN-acylhydrazone derivatives (PFUR 4, a-k) againstTrichomonas vaginalis.Trichomonas vaginalisATCC 30236 isolate was treated with seven concentrations of these compounds to determine the minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC50). In addition, compounds that displayed anti-T. vaginalisactivity were analyzed using thiobarbituric acid reactive substances (TBARS) assay and molecular docking. Cytotoxicity analysis was also performed in CHO-K1 cells.Results: The compounds PFUR 4a and 4b, at 6.25 µM, induced complete parasite death after 24 h of exposure with IC50of 1.69 µM and 1.98 µM, respectively. The results showed that lipid peroxidation is not involved in parasite death. Molecular docking studies predicted strong interactions of PFUR 4a and 4b withT. vaginalisenzymes, purine nucleoside phosphorylase, and lactate dehydrogenase, while only PFUR 4b interactedin silicowith thioredoxin reductase and methionine gamma-lyase. PFUR 4a and 4b led to a growth inhibition (< 20%) in CHO-K1 cells that was comparable to the drug of choice, with a promising selectivity index (> 7.4).Conclusions: Our results showed that PFUR 4a and 4b are promising molecules that can be used for the development of new trichomonacidal agents forT. vaginalis.
- 1 May 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 89, 284-287
Antiparasitic activity of 1,3-dioxolanes containing tellurium in Trichomonas vaginalis
- 1 May 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 89, 284-287
Antiparasitic activity of 1,3-dioxolanes containing tellurium in Trichomonas vaginalis